

Remarks

In the above referenced Office Action, the Examiner divided the claims into the following groups:

Group I Claims 1-5, 8, 9, and 20 drawn to a method of treating a viral disease by administering interferon-tau;

Group II Claims 21-28 drawn to a method of treating a condition associated with cellular proliferation by administering interferon-tau; and

Group III Claims 29-36 drawn to a method of treating an inflammatory disease by administering interferon-tau.

In response, the applicants elect Group I without traverse. Non-elected claims 21-36 have been canceled.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4402.

Respectfully submitted,

Date: October 27, 2003

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300